The Current State of Multidrug‐Resistant Gram‐Negative Bacilli in North America
- 1 February 2008
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 28 (2), 235-249
- https://doi.org/10.1592/phco.28.2.235
Abstract
Although much of today's media focuses on multidrug-resistant gram-positive bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, resistance within gram-negative bacilli continues to rise, occasionally creating situations in which few or no antibiotics that retain activity are available. Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella sp are emerging threats nationally. Although carbapenems are considered the antibiotic class of choice to treat ESBL-producing Enterobacteriaceae, the ability of these organisms to produce carbapenemases has now become apparent in some regions throughout the United States. Although still rare, Klebsiella sp that produce KPC-2 retain susceptibility only to tigecycline, polymyxins, and occasionally aminoglycosides. Multidrug resistance among Pseudomonas aeruginosa and Acinetobacter sp has always been apparent across many hospitals in the United States. Recent surveillance indicates increasing resistance to all currently available antibiotics, including carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides. Against many strains, only polymyxins retain activity; however, resistance has also been reported to these agents. Fortunately, resistance mechanisms such as metallo-beta-lactamases are still rare in the United States. As no new antibiotics with novel mechanisms against many of these gram-negative bacilli are expected to be developed in the foreseeable future, careful and conservative use of agents combined with good infection control practices is required.This publication has 135 references indexed in Scilit:
- Colistin Is Effective in Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa in Cancer PatientsAntimicrobial Agents and Chemotherapy, 2007
- Antimicrobial Susceptibility and Synergy Studies of Burkholderia cepacia Complex Isolated from Patients with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2007
- Susceptibility of Acinetobacter Strains Isolated from Deployed U.S. Military PersonnelAntimicrobial Agents and Chemotherapy, 2007
- Analysis of Antibiotic Resistance Genes in Multidrug-Resistant Acinetobacter sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical CenterAntimicrobial Agents and Chemotherapy, 2006
- Defining the Dosage Units for Colistin Methanesulfonate: Urgent Need for International HarmonizationAntimicrobial Agents and Chemotherapy, 2006
- In Vitro Activity of Tigecycline against Multiple-Drug-Resistant, Including Pan-Resistant, Gram-Negative and Gram-Positive Clinical Isolates from Greek HospitalsAntimicrobial Agents and Chemotherapy, 2006
- Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant Escherichia coli Clones in IsraelAntimicrobial Agents and Chemotherapy, 2006
- First Detection of the Plasmid-Mediated Class A Carbapenemase KPC-2 in Clinical Isolates of Klebsiella pneumoniae from South AmericaAntimicrobial Agents and Chemotherapy, 2006
- Antibiotic Coresistance in Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of TigecyclineAntimicrobial Agents and Chemotherapy, 2006
- Use of International Units When Dosing Colistin Will Help Decrease Confusion Related to Various Formulations of the Drug around the WorldAntimicrobial Agents and Chemotherapy, 2006